ACTRN12613000333718已完成不适用
A Double-blind Randomised Placebo-controlled Study of Topical Acitretin and Placebo for the Treatment of Facial Actinic Keratosis.Protocol Number: DP-001
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 40 Years 至 80 Years（—）
- 性别
- All
入选标准
- •At least 3, to a maximum of 25, visible or palpable AK lesions on the face determined by clinical diagnosis.
- •- Males, or postmenopausal/surgically sterile females.
- •- Willing and able to comply with the protocol and study requirements.
排除标准
- •- Atypical AK on the face.
- •- Diagnosis of SBCC on the face.
- •- Treatment with oral acitretin.
- •- Treatment with 5FU, imiquimod, diclofenac, PEP005 or topical retinoids on the face.
- •- Treatment with a dermatological procedure or surgery on the face.
- •- Other potentially confounding skin disorders on the face.
- •- Females of child bearing potential.
研究者
相似试验
Unknown
3 期
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 PneumoniaCOVID19 PneumoniaPACTR202106466447805Genentech Inc379
进行中（未招募）
不适用
A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo ParathyroidectomyReduction of hypercalcemia in subjects with primary hyperparathyroidism (HPT) who meet criteria for parathyroidectomy on the basis of corrected total serum calcium, but who are unable to undergo parathyroidectomy.MedDRA version: 12.0Level: LLTClassification code 10036693Term: Primary hyperparathyroidismEUCTR2009-012943-41-PTAmgen Inc160
进行中（未招募）
1 期
Study of the effects of blocking the enzyme PCSK9 on artery wall inflamatioMedDRA version: 18.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersHypercholesterolemiaEUCTR2015-003731-35-NLAmgen Inc120
已完成
3 期
A clinical trial to study the effects of the drug Asacol 4,8g/day (800 mg tables) in patients with active Ulceratice ColitisCTRI/2010/091/000387Tillotts Pharma AG280
招募中
1 期
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (VISTAS)Pruritus associated with Primary Sclerosing Cholangitis (PSC)MedDRA version: 20.1Level: LLTClassification code: 10036732Term: Primary sclerosing cholangitis Class: 10019805CTIS2023-505764-11-00Mirum Pharmaceuticals Inc.395